NASDAQ$HOLX

Hologic Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Hologic's financial results for Q3 2020 were announced, with revenue declining 3.5% due to the Cynosure divestiture, but organic revenue increasing 7.7% due to strong COVID test sales.

Hologic's Q3 2020 results showed a revenue decrease of 3.5% due to the Cynosure divestiture, but organic revenue grew by 7.7%. Molecular Diagnostics revenue increased significantly due to high demand for COVID-19 tests. The company launched a new ultrasound system in its Breast Health division and repaid $250 million of debt.

  • Revenue declined 3.5%, but organic revenue grew 7.7%.
  • Molecular Diagnostics revenue increased 169.3% due to strong demand for COVID-19 tests.
  • The Breast Health division launched the SuperSonic™ MACH 40 ultrasound system in the United States.
  • Cash flow from operations was $223 million, and $250 million of debt was repaid.

Headline financials

Total Revenue

$823M

Previous: $852M-3.5%
EPS (adj)

$0.75

Previous: $0.63+19.0%
Capital Expenditures

-$53.2M

Previous: -$37.8M-40.7%
Free Cash Flow

$401M

Previous: $364M+10.3%
Net Income

$136M

Previous: $93.9M+45.3%
Operating Income

$191M

Previous: $145M+31.5%
Gross Profit

$466M

Previous: $445M+4.8%
Cash & Equivalents

$744M

Previous: $428M+73.9%
Total Assets

$6.8B

Previous: $6.52B+4.3%
Stock-Based Comp

$19.9M

Previous: $13.9M+43.2%

Revenue & EPS history

Hologic · Revenue · Quarterly

$823M

Q3 2020-3.5%vs Q3 2019
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Hologic · $1.22B total across 3 segments · Q3 2020

  • Diagnostics
    $532M
  • Molecular Diagnostics
    $460M+169.3%
  • Breast Health
    $224M

Forward guidance

Hologic provided financial guidance for the fourth quarter of fiscal 2020, anticipating strong demand for COVID tests and ongoing recovery in other divisions.

Tailwinds

  • Revenue between $925 million and $1,025 million, representing a 6.8% to 18.4% increase.
  • Organic revenue growth between 17.4% and 30.3%.
  • GAAP EPS between $0.73 and $0.93.
  • Non-GAAP EPS between $0.95 and $1.15, representing a 46.2% to 76.9% increase.
  • Strong demand for COVID tests and ongoing recovery in other divisions are enabling the company to provide guidance.

Headwinds

  • Business environment remains highly fluid and unpredictable.
  • Guidance ranges are wider than usual due to uncertainty.
  • Constant currency guidance assumes foreign exchange rates are the same as in fiscal 2019.
  • Organic revenue guidance excludes divested and acquired businesses.
  • The guidance is based on a full year non-GAAP tax rate of approximately 22.75%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

-0.5%

Avg return

Earnings day

+0.2%

Avg return

5 days after

-0.1%

Avg return

30 days after

49%

35 / 72 earnings

Positive

+12.3%

Q3 2020

Best reaction

-11.4%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q1 2026+0.0%-0.6%+0.7%
Q4 2025+0.1%+0.1%+0.9%
Q3 2025+2.8%+4.4%+3.3%
Q2 2025-5.6%-3.2%+8.5%
Q1 2025-10.1%-11.4%-11.3%
Q4 2024-4.3%-4.3%-6.6%
Q3 2024+4.9%+6.4%+2.2%
Q2 2024+0.3%-0.2%-3.3%
Q1 2024-2.7%-0.4%-1.1%
Q4 2023+5.7%+5.4%+0.1%
Q3 2023-5.1%-5.9%-5.4%
Q2 2023-2.4%-2.6%-8.3%
Q1 2023+3.8%+3.6%-1.1%
Q4 2022+10.8%+12.4%+13.8%
Q3 2022+1.0%+1.3%-3.4%
Q2 2022+1.2%+3.4%+9.8%
Q1 2022+4.0%+3.8%+2.4%
Q4 2021-3.3%-5.9%-0.3%
Q3 2021+2.3%+5.0%+9.7%
Q2 2021-9.1%-9.9%-13.4%
Q1 2021+1.7%+11.2%-3.3%
Q4 2020+6.6%-5.0%+1.7%
Q3 2020+12.3%+14.8%-2.8%
Q2 2020+2.9%+2.6%+8.9%
Q1 2020-0.7%-1.8%-13.7%
Q4 2019-4.0%+8.8%+10.3%
Q3 2019-1.3%-6.5%-4.1%
Q2 2019-0.1%+0.7%-5.1%
Q1 2019+0.6%-0.5%+8.6%
Q4 2018+4.9%+1.2%+3.7%
Q3 2018-3.5%-1.9%-7.5%
Q2 2018-6.9%-6.8%-3.9%
Q1 2018-6.7%-6.6%-2.2%
Q4 2017+0.4%+2.9%+8.1%
Q3 2017-9.3%-11.3%-12.5%
Q2 2017-4.3%-5.1%-2.0%
Q1 2017-2.6%-2.9%+1.8%
Q4 2016+4.3%+8.5%+6.3%
Q3 2016+3.9%+5.8%+5.3%
Q2 2016-10.0%
Q1 2016-9.2%
Q4 2015+0.6%
Q3 2015+8.6%
Q2 2015+2.1%
Q1 2015+5.1%
Q4 2014-1.7%
Q3 2014+2.1%
Q2 2014+8.1%
Q1 2014-5.9%
Q4 2013-6.9%
Q3 2013-0.2%
Q2 2013+0.1%
Q1 2013-4.1%
Q4 2012-0.3%
Q3 2012-0.4%
Q2 2012-11.4%
Q1 2012+5.2%
Q4 2011-4.0%
Q3 2011-3.9%
Q2 2011-0.6%
Q1 2011+0.0%
Q4 2010+1.2%
Q3 2010+1.2%
Q2 2010-2.6%
Q1 2009-2.8%
Q1 2010-1.1%
Q2 2009+2.9%
Q4 2007+2.9%
Q4 2009+2.9%
Q3 2009-3.0%
Q3 2008-3.0%
Q4 2008-3.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro